4 Consideration of the evidence

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of afatinib, having considered evidence on the nature of epidermal growth factor receptor (EGFR) mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) and the value placed on the benefits of afatinib by people with the condition, those who represent them, and clinical specialists. It also took into account the effective use of NHS resources.

Clinical effectiveness

4.1 The Committee discussed current clinical practice for treating EGFR mutation-positive locally advanced or metastatic NSCLC. The clinical specialists highlighted that the standard first choice of treatment for NSCLC with EGFR-positive tyrosine kinase mutations was a tyrosine kinase inhibitor, which is in line with NICE's technology appraisal guidance on erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (NICE technology appraisal guidance 258) and gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NICE technology appraisal guidance 192). The Committee was also aware of evidence presented in the manufacturer's submission which stated that 99% of eligible patients receive either erlotinib or gefitinib as a first-line treatment. The Committee concluded that treatment with erlotinib and gefitinib is standard practice for most people presenting with EGFR mutation-positive locally advanced or metastatic NSCLC.

4.2 The Committee discussed the place of afatinib in the treatment pathway in relation to current clinical practice in the NHS. The Committee noted that the manufacturer's submission only presented evidence on the use of afatinib in people who have not been previously treated with a tyrosine kinase inhibitor and this was in line with afatinib's marketing authorisation. The Committee heard from the clinical specialists that if recommended, afatinib would be likely to be considered alongside erlotinib and gefitinib for locally advanced or metastatic NSCLC that had not been treated with a tyrosine kinase inhibitor. The Committee also heard from the clinical specialists that afatinib has a different adverse reaction profile from the other tyrosine kinase inhibitors, and that patients differ in their ability to tolerate different adverse reactions. They highlighted that if afatinib was recommended, it would enable clinicians to choose the tyrosine kinase inhibitor with the adverse reaction profile best suited to the individual patient. The Committee heard from clinical specialists that the irreversible binding of afatinib to the ErbB family of receptors (compared with the reversible binding of gefitinib and erlotinib) is believed to help reduce the possibility of resistance and delay its development. Therefore, the Committee concluded that erlotinib and gefitinib were appropriate comparators and that further first-line treatment options for EGFR mutation-positive locally advanced or metastatic NSCLC would be of value to clinicians and patients.

4.3 The Committee discussed the clinical effectiveness evidence, focussing on the results of the LUX-Lung 3 and 6 trials which compared afatinib with pemetrexed plus cisplatin (LUX-Lung 3) and gemcitabine plus cisplatin (LUX-Lung 6). The Committee heard from the clinical specialists that the chemotherapy doublets used in these trials were regarded as best clinical practice at the time. It noted that both trials reported a statistically significant increase in median progression-free survival with afatinib compared with chemotherapy. However, no statistically significant difference in overall survival was seen in LUX-Lung 3 or LUX-Lung 6 because the data were immature and could have been confounded by treatment crossover between the treatment and control arms in both trials. Therefore, the Committee agreed that there was sufficient evidence to conclude that afatinib was clinically effective in prolonging progression-free survival but because of the immaturity of the overall survival data available, there was uncertainty about whether treatment with afatinib resulted in an overall survival benefit compared with chemotherapy.

4.4 The Committee considered the pre-specified subgroup analyses of the LUX–Lung 3 progression-free survival data for baseline characteristics such as gender, age, family origin and common EGFR mutations, presented by the manufacturer in response to a request from the ERG for clarification. These analyses suggested there was no statistically significant difference in progression-free survival for any subgroup with the exception of common EGFR mutations compared with other EGFR mutations. The manufacturer's exploratory data (see section 3.21) suggested that people of Asian family origin may have a better progression-free survival than non-Asian patients. The Committee also noted that approximately one third of patients in LUX-Lung 3 were non-Asian, which represented a small number of patients and that the trial was underpowered to detect differences in progression-free survival based on ethnicity. The Committee noted that the results of a statistical test presented by the manufacturer for interaction between family origin and treatment effect were not statistically significant. However, the Committee also noted that the ERG analysis of cumulative mortality hazard in LUX-Lung 3 showed large differences in progression-free survival between the Asian and non-Asian populations both in the control and treatment arms of the trials, indicating that ethnicity may impact on the effectiveness of treatment.

4.5 The Committee considered whether there was any biologically plausible reason why the effectiveness of afatinib would differ according to a person's family origin. The clinical specialists stated that based on their limited use of afatinib in small numbers of patients in England, there were no physiological differences between Asian and non-Asian patients that would explain the apparent differences in the effectiveness of afatinib. They emphasised that differences in the effectiveness of afatinib in NSCLC are more likely to be determined by EGFR mutation status rather than ethnicity; patients who are EGFR mutation-positive have similar response rates regardless of ethnic background. The Committee heard from the clinical specialists that the differences in the outcomes between the Asian and non-Asian population may be explained by the different standard of care and drug regimens used at trial centres in Asian compared with non-Asian countries, some of which may be more clinically effective than other regimens. Therefore, the Committee concluded that although there was uncertainty about the underlying reason, on balance the ERG analysis showed that ethnicity had an impact on the effectiveness of afatinib, and that the effectiveness of afatinib in clinical practice in England would be best represented by clinical effectiveness data in a non-Asian group.

4.6 The Committee considered the evidence presented on the relative clinical effectiveness of afatinib compared with erlotinib and gefitinib. The Committee noted comments from the clinical specialists that the comparator chemotherapy regimen used in the LUX-Lung 3 trial, namely pemetrexed plus cisplatin, was considered to be more effective than the comparator chemotherapy regimens used in the erlotinib and gefitinib trials. The Committee noted that because there were no head-to-head trials comparing the clinical effectiveness of afatinib with erlotinib and gefitinib, the manufacturer presented a network meta-analysis (see sections 3.6 to 3.9). The Committee considered the methodology of the manufacturer's network mixed treatment comparison and the critique by the ERG. The Committee considered the ERG comments that in all 7 studies that included EGFR mutation-positive patients, the overall survival curves of the treatment arms cross. This indicated that the proportional hazards assumption had not been met, that is, the relative treatment effects captured by the hazard ratios were not constant across all time points. The Committee acknowledged that if the proportional hazards assumption was violated then using hazard ratios to form a network meta-analysis is not appropriate. It also heard from the ERG that although the manufacturer's original extrapolation of progression-free survival included in the economic model matched the trial data, ERG analysis of the Weibull models generated by the manufacturer to represent survival for patients receiving afatinib or pemetrexed plus cisplatin based on non-informative censoring (when each patient has a censoring time that is statistically independent of their treatment failure time) did not accurately reflect the experience of patients in LUX-Lung 3, especially for progression-free survival. The Committee acknowledged the ERG's view that based on a visual analysis, a 2-phase exponential model was a better fit to the trial data and therefore more accurately represented survival for patients treated with afatinib compared with pemetrexed plus cisplatin over the long term. The Committee therefore concluded that the underlying methodology of the mixed treatment comparison was not sufficiently robust.

4.7 The Committee also noted that the manufacturer's original mixed treatment model included trials of patients with mixed or unknown EGFR mutation status as well as patients with EGFR mutation-positive disease. It acknowledged that this had been necessary to enable the manufacturer to join the network in the mixed treatment comparison to ensure all the tyrosine kinase inhibitors could be compared. However, the Committee noted the ERG comment that differences in patient characteristics between studies of patients of EGFR mutation-positive NSCLC and those of unknown or mixed EGFR mutation status (for example, in relation to the proportion of men, those who have never smoked and patients with adenocarcinoma) meant that the populations of the included trials were not sufficiently similar to be included in a mixed treatment comparison. The Committee considered the manufacturer's mixed treatment comparison that was limited to EGFR mutation-positive patients to be the most appropriate because it is in line with the marketing authorisation for afatinib and because of the widely accepted improved prognosis of EGFR mutation-positive patients. It noted that this analysis gave a slightly improved hazard ratio for afatinib compared with erlotinib and gefitinib. The Committee noted the statements from the manufacturer that the similarity of the results of the original and EGFR mutation-positive subgroup analysis demonstrated the robustness of the mixed treatment comparison. However, it noted that there were fewer than 50 patients included from the gefitinib trial in the EGFR mutation-positive subgroup analysis.

4.8 The Committee also noted that the mixed treatment comparison of the EGFR mutation-positive subgroup included studies of predominantly Asian populations. It considered that a mixed treatment comparison for EGFR mutation-positive patients of non-Asian ethnicity would be more clinically relevant to people with NSCLC in England, but that this had not been done. The Committee noted that the European public assessment report considered the benefits of afatinib to be 'in line with the other tyrosine kinase inhibitors' and heard from the clinical specialists that based on their limited experience with small numbers of patients, afatinib has a similar efficacy to the tyrosine kinase inhibitors erlotinib and gefitinib. The Committee concluded that evidence from the mixed treatment comparison was not sufficiently robust because of the underlying methodology (violation of the proportional hazards assumption) and because it was based on a predominantly Asian population, who were not considered generalisable to the UK. The Committee concluded that on balance afatinib is likely to have similar clinical efficacy to erlotinib and gefitinib. The Committee was also aware of the LUX-Lung 7 study (due to report in 2015) which would provide more evidence on the relative clinical effectiveness of afatinib compared with gefitinib.

4.9 The Committee considered the adverse reactions experienced by patients receiving treatment for locally advanced or metastatic EGFR mutation-positive NSCLC in the pivotal clinical trials with afatinib (LUX-Lung 3) compared with erlotinib (EURTAC) and gefitinib (IPASS). It noted that the incidence of diarrhoea and rash was considerably higher with afatinib compared with erlotinib and gefitinib. The patient expert stated that patients found adverse reactions with afatinib to be more easily tolerated than the adverse effects associated with many of the chemotherapy regimens. The Committee also heard from clinical specialists that diarrhoea is easily managed by dose reduction and drugs, which is demonstrated by the low rate of discontinuation because of diarrhoea (1.3%). The Committee further noted the conclusions of the European public assessment report that afatinib had similar toxicity to erlotinib and gefitinib. The Committee agreed that although afatinib has a higher rate of diarrhoea and rash, these were well managed in clinical practice. The Committee concluded that although afatinib has a different adverse reaction profile from erlotinib and gefitinib, overall the toxicity of the tyrosine kinase inhibitors was similar.

Cost effectiveness

4.10 The Committee considered the manufacturer's base-case cost-effectiveness analysis incorporating the patient access schemes for afatinib, erlotinib and gefitinib, and the ERG critique. The Committee considered the population included in the base-case model. It noted that the population in the model (that is, people with mixed EGFR status and a combination of Asian and non-Asian patients) was not relevant to clinical practice in England (that is, EGFR mutation-positive and predominantly non-Asian). It also noted that methodological issues with the mixed treatment comparison (related to the violation of the assumption of proportional hazards and the extrapolation of progression-free survival and overall survival with afatinib) have an impact on the credibility of the economic model. The Committee considered whether it was possible to model the cost effectiveness of afatinib compared with erlotinib and gefitinib based on assumptions of the same clinical efficacy (in a similar way to that in NICE technology appraisal guidance 258). The Committee heard from the ERG that this was not possible because the structure of the model relies on using a single survival model formulation through a network of hazard ratios (assuming that the proportional hazard assumption applies throughout). Any attempt at modifying it would involve creating a new model. The Committee concluded that methodological issues related to the assumption of proportional hazards, the extrapolation of progression-free survival and the population of the base-case model prevented the Committee from assessing the cost effectiveness of afatinib compared with erlotinib and gefitinib based on the manufacturer's model. Therefore a most plausible ICER could not be estimated.

4.11 The Committee considered the exploratory cost analysis presented by the ERG in which the average daily acquisition costs of afatinib, erlotinib and gefitinib were compared and which included the patient access schemes agreed by the Department of Health for each treatment. The Committee considered the 2 scenarios presented, firstly in which progression-free survival and overall survival were the same for all tyrosine kinase inhibitors, and secondly in which overall survival was the same but progression-free survival depended on the results of the pivotal trials. The Committee noted that the total costs, which incorporate the patient access schemes for afatinib and erlotinib have been designated as commercial in confidence and cannot be reported here. It also noted that the complexities of the patient access scheme make it difficult to assess the daily cost of gefitinib, which varies depending on the proportion of patients who stop taking gefitinib before the third pack is received. The Committee heard from the ERG that for consistency with the assumptions in the erlotinib appraisal, their analysis assumed that 5% of patients stopped taking gefitinib before the third pack and therefore did not incur any cost for gefitinib treatment. Without robust evidence on differences in the effectiveness of afatinib compared with erlotinib and gefitinib, the Committee considered the scenario based on equal progression-free survival and overall survival to be the most appropriate. It also accepted that in clinical practice the tyrosine kinase inhibitors were likely to have similar efficacy (see section 4.8). The Committee concluded that assuming progression-free survival for afatinib is equivalent to the other tyrosine kinase inhibitors, afatinib is a cost-effective use of NHS resources because it has comparable costs to erlotinib. Although the gefitinib patient access scheme makes it difficult to assess the daily acquisition cost of gefitinib, the Committee concluded that on balance afatinib was likely to have similar cost effectiveness to gefitinib. The Committee therefore concluded that afatinib could be considered an appropriate treatment alternative to erlotinib and gefitinib.

4.12 The Committee considered the exploratory analyses conducted by the ERG, which estimated the cost effectiveness of afatinib compared with cisplatin in combination with pemetrexed, based on the trial data, noting that these analyses did not account for crossover in the trial, and could therefore be considered conservative. Although the comparator used in this analysis was not included in the scope, the Committee considered that it provided reassurance that afatinib was likely to be a cost-effective use of NHS resources compared with the chemotherapy that was the gold standard at the time the trials for afatinib were designed (before the tyrosine kinase inhibitors became established practice). The Committee concluded that on balance, based on all the evidence considered, afatinib is considered to be a reasonable alternative treatment option compared with erlotinib and gefitinib, in people with locally advanced or metastatic EGFR mutation-positive NSCLC that has not been previously treated with an EGFR tyrosine kinase inhibitor or chemotherapy.

4.13 The Committee noted that most patients with locally advanced or metastatic EGFR mutation-positive NSCLC receive a tyrosine kinase inhibitor as first-line treatment. However, the clinical specialists advised that there is regional variation in the speed of EGFR testing and that it generally takes between 1 and 3 weeks to get the results. The clinical specialists also stated that a minority of patients with aggressive disease will therefore need treatment before EGFR mutation status is confirmed and will start treatment with chemotherapy (a third generation agent plus platinum) and receive a tyrosine kinase inhibitor as second-line treatment. The Committee noted that there is only limited evidence in small numbers of patients for the effectiveness of afatinib after prior chemotherapy. However, it acknowledged that the phase II LUX-Lung 2 trial suggested that afatinib is also effective when used as second-line treatment after chemotherapy. The Committee concluded that afatinib is likely to be clinically and cost effective as a second-line treatment for the minority of patients who have received chemotherapy as first-line treatment. The Committee therefore recommended afatinib as a treatment option in line with its marketing authorisation; that is, if the person has not previously had an EGFR tyrosine kinase inhibitor.

4.14 The Committee considered whether afatinib should be considered as an innovative technology, given that it is another tyrosine kinase inhibitor for the treatment of EGFR mutation-positive NSCLC. The Committee noted that afatinib irreversibly binds to the ErbB family of receptors making it different, in vitro, from the tyrosine kinase inhibitors erlotinib and gefitinib (see section 2.1). The Committee heard from the clinical specialists that there is the possibility that, because of its mechanism of action, afatinib may be less likely to be associated with the development of resistance to tyrosine kinase inhibitors. However, the Committee concluded that the clinical evidence did not suggest that the mode of action for afatinib led to any significant benefit in clinical effectiveness compared with erlotinib and gefitinib. The Committee concluded that afatinib could not be considered to show significant innovation over the other tyrosine kinase inhibitors. The Committee again acknowledged the importance of the ongoing LUX-Lung 7 trial to provide further evidence on the clinical effectiveness of afatinib compared with gefitinib.

Summary of Appraisal Committee's key conclusions

Key conclusion

Afatinib is recommended as an option, within its marketing authorisation, for treating adults with locally advanced or metastatic non-small-cell lung cancer only if:

  • the tumour tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and

  • the person has not previously had an EGFR-TK inhibitor and

  • the manufacturer provides afatinib with the discount agreed in the patient access scheme.

The Committee concluded that on balance afatinib is likely to have similar clinical efficacy to erlotinib and gefitinib.

The Committee concluded that methodological issues related to the assumption of proportional hazards, the extrapolation of progression-free survival and the population of the base-case model prevented the Committee from assessing the cost effectiveness of afatinib compared with erlotinib and gefitinib based on the manufacturer's model. Therefore a most plausible ICER could not be estimated.

The Committee concluded that on balance, based on all the evidence considered, afatinib is considered to be a reasonable alternative treatment option compared with erlotinib and gefitinib, in people with locally advanced or metastatic EGFR mutation-positive NSCLC that has not been previously treated with an EGFR tyrosine kinase inhibitor or chemotherapy.

The Committee concluded that afatinib is likely to be clinically and cost effective as a second-line treatment for the minority of patients who have received chemotherapy as first-line treatment. The Committee therefore recommended afatinib as a treatment option in line with its marketing authorisation.

See sections 1.1, 4.8, 4.10, 4.12 and 4.13.

Current practice

Clinical need of patients, including the availability of alternative treatments#

The clinical specialists highlighted that the standard first choice of treatment for NSCLC with EGFR-positive tyrosine kinase mutations was a tyrosine kinase inhibitor, which is in line with NICE technology appraisal guidance 258 and 192.

The Committee concluded that treatment with erlotinib or gefitinib is standard practice for most people presenting with EGFR mutation-positive locally advanced or metastatic NSCLC.

The Committee also concluded that erlotinib and gefitinib were appropriate comparators and that further first-line treatment options for EGFR mutation-positive locally advanced or metastatic NSCLC would be of value to clinicians and patients.

See sections 4.1 and 4.2.

The technology

Proposed benefits of the technology

The Committee heard from clinical specialists that the irreversible binding of afatinib to the ErbB family of receptors (compared with the reversible binding of gefitinib and erlotinib) is believed to help reduce the possibility of resistance and delay its development.

See section 4.2.

How innovative is the technology in its potential to make a significant and substantial impact on health-related benefits?

The Committee concluded that the clinical evidence did not suggest that the mode of action for afatinib led to any significant benefit in clinical effectiveness compared with erlotinib and gefitinib. The Committee concluded that afatinib could not be considered to show significant innovation over the other tyrosine kinase inhibitors.

See section 4.14.

What is the position of the treatment in the pathway of care for the condition?

The Committee heard from the clinical specialists that if recommended, afatinib would be likely to be considered alongside erlotinib and gefitinib for locally advanced or metastatic NSCLC that had not been treated with a tyrosine kinase inhibitor.

See section 4.2.

Adverse reactions

The Committee concluded that although afatinib has a different adverse reaction profile from erlotinib and gefitinib, overall the toxicity of the tyrosine kinase inhibitors was similar.

See section 4.9.

Evidence for clinical effectiveness

Availability, nature and quality of evidence

The Committee heard from the clinical specialists that the chemotherapy doublets used in LUX-lung 3 and LUX-lung 6 were regarded as best clinical practice at the time.

The Committee noted that because there were no head-to-head trials comparing the clinical effectiveness of afatinib with erlotinib and gefitinib, the manufacturer presented a network meta-analysis.

The Committee concluded that evidence from the mixed treatment comparison was not sufficiently robust because of the underlying methodology (violation of the proportional hazards assumption) and because it was based on a predominantly Asian population, who were not considered generalisable to the UK.

See sections 4.3, 4.6 and 4.8.

Relevance to general clinical practice in the NHS

The Committee concluded that a mixed treatment comparison for EGFR mutation-positive patients of non-Asian ethnicity would be more clinically relevant to people with NSCLC in England, but that this had not been done.

See section 4.8.

Uncertainties generated by the evidence

The LUX-Lung trials provided sufficient evidence to conclude that afatinib was clinically effective in prolonging progression-free survival but because of the immaturity of the overall survival data available, there was uncertainty about whether treatment with afatinib resulted in an overall survival benefit compared with chemotherapy.

The Committee concluded that evidence from the mixed treatment comparison was not sufficiently robust because of the underlying methodology (violation of the proportional hazards assumption) and because it was based on a predominantly Asian population, who were not considered generalisable to the UK.

See sections 4.3 and 4.8.

Are there any clinically relevant subgroups for which there is evidence of differential effectiveness?

The Committee concluded that although there was uncertainty about the underlying reason, on balance the ERG analysis showed that ethnicity had an impact on the effectiveness of afatinib in clinical practice, and that the effectiveness of afatinib in clinical practice in England would be best represented by clinical effectiveness data in a non-Asian group.

See section 4.5.

Estimate of the size of the clinical effectiveness including strength of supporting evidence

The Committee concluded that on balance afatinib is likely to have similar clinical efficacy to erlotinib and gefitinib.

See section 4.6.

Evidence for cost effectiveness

Availability and nature of evidence

The manufacturer of afatinib submitted cost-effectiveness evidence as part of its submission, based on a mixed treatment comparison.

The ERG submitted an exploratory cost analysis and an exploratory economic analysis of afatinib compared with cisplatin in combination with pemetrexed, based on the trial data.

See sections 4.10 to 4.12.

Uncertainties around and plausibility of assumptions and inputs in the economic model

The Committee concluded that methodological issues related to the assumption of proportional hazards, the extrapolation of progression-free survival and the population of the base-case model prevented the Committee from assessing the cost effectiveness of afatinib compared with erlotinib and gefitinib based on the manufacturer's model. Therefore a most plausible ICER could not be estimated.

See section 4.10.

Incorporation of health-related quality-of-life benefits and utility values: have any potential significant and substantial health-related benefits been identified that were not included in the economic model, and how have they been considered?

The Committee did not draw any specific conclusions about the health-related quality-of-life benefits and utility values.

Are there specific groups of people for whom the technology is particularly cost effective?

None were identified.

What are the key drivers of cost effectiveness?

The main drivers of cost effectiveness were: the mixed treatment comparison-based hazard ratios for progression-free and overall survival, the cost per month for the progression-free health state and the cost per month for the best supportive care period of the progressive disease health state.

See section 3.19.

Most likely cost-effectiveness estimate (given as an ICER)

A most plausible ICER could not be estimated.

The Committee concluded that on balance, based on all the evidence considered, afatinib is considered to be a reasonable alternative treatment option compared with erlotinib and gefitinib, in people with locally advanced or metastatic EGFR mutation-positive NSCLC that has not been previously treated with an EGFR tyrosine kinase inhibitor or chemotherapy.

See sections 4.10 and 4.12.

Additional factors taken into account

Patient access schemes (PPRS)

The manufacturer of afatinib has agreed a patient access scheme with the Department of Health in which a confidential discount is applied at the point of purchase or invoice.

See section 2.3.

End-of-life considerations

The manufacturer did not make a case for afatinib to be considered under the end of life criteria.

Equalities considerations and social value judgements

No equality and diversity issues relating to population groups protected by equality legislation were highlighted when the scope for this appraisal was developed, or during the appraisal.

  • National Institute for Health and Care Excellence (NICE)